Charles River Laboratories International, Inc.’s stock price soars to $136.97, marking an impressive +18.68% surge in value

Charles River Laboratories International, Inc. (CRL)

136.97 USD +21.56 (+18.68%) Volume: 4.23M

Charles River Laboratories International, Inc.’s stock price has surged to 136.97 USD, marking a significant increase of +18.68% in this trading session, backed by a robust trading volume of 4.23M. Despite the impressive session performance, the company’s stock remains down by -25.80% year-to-date, reflecting the volatility in the market.

Latest developments on Charles River Laboratories International, Inc.

Charles River Laboratories stock price soared today after the firm announced a shake-up of its board and a strategic review. The Q1 earnings beat consensus expectations, leading to an increase in demand stabilization and a surge in stock trading. The company also appointed new directors following an agreement and raised its profit forecast for 2025. This positive news resulted in a 22.4% jump in stock price. The strategic review aims to enhance long-term stockholder value amidst regulatory uncertainty and sliding revenue. Overall, Charles River Laboratories is experiencing its best day in 13 years, with shares surging on strong Q1 results and upgraded outlook.

A look at Charles River Laboratories International, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

According to Smartkarma Smart Scores, Charles River Laboratories International, Inc. has a positive long-term outlook overall. With a high score in the value category, the company is seen as offering good value for investors. However, the low dividend score may deter income-focused investors. In terms of growth, Charles River Laboratories scores moderately, indicating potential for expansion in the future. The company’s resilience score is strong, suggesting that it can weather economic uncertainties. Additionally, its momentum score is also solid, indicating positive market sentiment.

Charles River Laboratories International, Inc. is a company that provides research tools and support services for drug discovery and development. They specialize in offering animal research models essential for the development of new drugs, devices, and therapies. The company serves a wide range of clients, including pharmaceutical and biotechnology companies, hospitals, and academic institutions. Based on the Smartkarma Smart Scores, Charles River Laboratories shows promise for long-term growth and value, despite having a lower dividend score.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma